Medical - Distribution
Compare Stocks
4 / 10Stock Comparison
GRDN vs CCRN vs PINC vs OMCL
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Care Facilities
Medical - Healthcare Information Services
Medical - Healthcare Information Services
GRDN vs CCRN vs PINC vs OMCL — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Medical - Distribution | Medical - Care Facilities | Medical - Healthcare Information Services | Medical - Healthcare Information Services |
| Market Cap | $2.30B | $423M | $2.34B | $1.97B |
| Revenue (TTM) | $1.46B | $761M | $1.00B | $1.23B |
| Net Income (TTM) | $53M | $-99M | $-24M | $20M |
| Gross Margin | 20.2% | 18.2% | 72.6% | 43.5% |
| Operating Margin | 6.4% | -0.9% | -0.0% | 2.7% |
| Forward P/E | 29.6x | 133.8x | 20.8x | 22.4x |
| Total Debt | $37M | $2M | $282M | $204M |
| Cash & Equiv. | $66M | $109M | $84M | $197M |
GRDN vs CCRN vs PINC vs OMCL — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Sep 24 | May 26 | Return |
|---|---|---|---|
| Guardian Pharmacy S… (GRDN) | 100 | 216.0 | +116.0% |
| Cross Country Healt… (CCRN) | 100 | 97.4 | -2.6% |
| Premier, Inc. (PINC) | 100 | 140.6 | +40.6% |
| Omnicell, Inc. (OMCL) | 100 | 99.4 | -0.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: GRDN vs CCRN vs PINC vs OMCL
Each card shows where this stock fits in a portfolio — not just who wins on paper.
GRDN carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 17.9%, EPS growth 144.1%, 3Y rev CAGR 16.8%
- 126.7% 10Y total return vs PINC's -4.6%
- 17.9% revenue growth vs CCRN's -21.6%
- 3.6% margin vs CCRN's -13.0%
CCRN is the clearest fit if your priority is income & stability and sleep-well-at-night.
- Dividend streak 1 yrs, beta 0.78
- Lower volatility, beta 0.78, Low D/E 0.7%, current ratio 3.78x
- Beta 0.78, current ratio 3.78x
PINC is the #2 pick in this set and the best alternative if value and stability is your priority.
- Lower P/E (20.8x vs 22.4x)
- Beta 0.07 vs OMCL's 1.34
- 3.0% yield; 1-year raise streak; the other 3 pay no meaningful dividend
OMCL is the clearest fit if your priority is momentum.
- +75.9% vs CCRN's -5.4%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 17.9% revenue growth vs CCRN's -21.6% | |
| Value | Lower P/E (20.8x vs 22.4x) | |
| Quality / Margins | 3.6% margin vs CCRN's -13.0% | |
| Stability / Safety | Beta 0.07 vs OMCL's 1.34 | |
| Dividends | 3.0% yield; 1-year raise streak; the other 3 pay no meaningful dividend | |
| Momentum (1Y) | +75.9% vs CCRN's -5.4% | |
| Efficiency (ROA) | 13.4% ROA vs CCRN's -19.8%, ROIC 35.8% vs -0.9% |
GRDN vs CCRN vs PINC vs OMCL — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
GRDN vs CCRN vs PINC vs OMCL — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
GRDN leads in 2 of 6 categories
CCRN leads 1 • PINC leads 1 • OMCL leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
Evenly matched — GRDN and PINC and OMCL each lead in 2 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
GRDN is the larger business by revenue, generating $1.5B annually — 1.9x CCRN's $761M. GRDN is the more profitable business, keeping 3.6% of every revenue dollar as net income compared to CCRN's -13.0%. On growth, OMCL holds the edge at +14.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $1.5B | $761M | $1.0B | $1.2B |
| EBITDAEarnings before interest/tax | $112M | $9M | $118M | $111M |
| Net IncomeAfter-tax profit | $53M | -$99M | -$24M | $20M |
| Free Cash FlowCash after capex | $70M | $41M | $265M | $112M |
| Gross MarginGross profit ÷ Revenue | +20.2% | +18.2% | +72.6% | +43.5% |
| Operating MarginEBIT ÷ Revenue | +6.4% | -0.9% | -0.0% | +2.7% |
| Net MarginNet income ÷ Revenue | +3.6% | -13.0% | -2.4% | +1.7% |
| FCF MarginFCF ÷ Revenue | +4.8% | +5.4% | +26.4% | +9.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +2.2% | -100.0% | -3.3% | +14.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +40.0% | -6.0% | -70.0% | +2.7% |
Valuation Metrics
CCRN leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
At 46.5x trailing earnings, GRDN trades at a 95% valuation discount to OMCL's 978.1x P/E. On an enterprise value basis, GRDN's 20.4x EV/EBITDA is more attractive than CCRN's 23.7x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $2.3B | $423M | $2.3B | $2.0B |
| Enterprise ValueMkt cap + debt − cash | $2.3B | $317M | $2.5B | $2.0B |
| Trailing P/EPrice ÷ TTM EPS | 46.51x | -4.47x | 128.45x | 978.10x |
| Forward P/EPrice ÷ next-FY EPS est. | 29.62x | 133.84x | 20.79x | 22.36x |
| PEG RatioP/E ÷ EPS growth rate | 2.48x | — | — | — |
| EV / EBITDAEnterprise value multiple | 20.40x | 23.75x | 21.35x | 23.56x |
| Price / SalesMarket cap ÷ Revenue | 1.59x | 0.40x | 2.31x | 1.66x |
| Price / BookPrice ÷ Book value/share | 10.54x | 1.31x | 1.70x | 1.63x |
| Price / FCFMarket cap ÷ FCF | 28.47x | 10.55x | 7.33x | 22.68x |
Profitability & Efficiency
GRDN leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
GRDN delivers a 25.4% return on equity — every $100 of shareholder capital generates $25 in annual profit, vs $-27 for CCRN. CCRN carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to PINC's 0.18x. On the Piotroski fundamental quality scale (0–9), OMCL scores 7/9 vs PINC's 4/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | +25.4% | -27.1% | -1.6% | +1.6% |
| ROA (TTM)Return on assets | +13.4% | -19.8% | -0.8% | +1.0% |
| ROICReturn on invested capital | +35.8% | -0.9% | +0.0% | +0.3% |
| ROCEReturn on capital employed | +41.5% | -0.8% | +0.0% | +0.3% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 6 | 4 | 7 |
| Debt / EquityFinancial leverage | 0.17x | 0.01x | 0.18x | 0.17x |
| Net DebtTotal debt minus cash | -$28M | -$106M | $198M | $8M |
| Cash & Equiv.Liquid assets | $66M | $109M | $84M | $197M |
| Total DebtShort + long-term debt | $37M | $2M | $282M | $204M |
| Interest CoverageEBIT ÷ Interest expense | 129.16x | -1.39x | 1.13x | 18.41x |
Total Returns (Dividends Reinvested)
GRDN leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in GRDN five years ago would be worth $22,675 today (with dividends reinvested), compared to $3,062 for OMCL. Over the past 12 months, OMCL leads with a +75.9% total return vs CCRN's -5.4%. The 3-year compound annual growth rate (CAGR) favors GRDN at 31.4% vs CCRN's -17.7% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | +22.9% | +62.4% | — | -4.0% |
| 1-Year ReturnPast 12 months | +40.5% | -5.4% | +24.0% | +75.9% |
| 3-Year ReturnCumulative with dividends | +126.7% | -44.3% | +14.8% | -33.3% |
| 5-Year ReturnCumulative with dividends | +126.8% | -22.5% | -9.2% | -69.4% |
| 10-Year ReturnCumulative with dividends | +126.7% | -10.5% | -4.6% | +36.3% |
| CAGR (3Y)Annualised 3-year return | +31.4% | -17.7% | +4.7% | -12.6% |
Risk & Volatility
PINC leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
PINC is the less volatile stock with a 0.07 beta — it tends to amplify market swings less than OMCL's 1.34 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PINC currently trades 98.2% from its 52-week high vs OMCL's 78.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.04x | 0.78x | 0.07x | 1.34x |
| 52-Week HighHighest price in past year | $41.36 | $14.99 | $28.79 | $55.00 |
| 52-Week LowLowest price in past year | $19.17 | $7.43 | $20.62 | $24.23 |
| % of 52W HighCurrent price vs 52-week peak | +87.7% | +87.3% | +98.2% | +78.8% |
| RSI (14)Momentum oscillator 0–100 | 47.4 | 53.1 | 65.0 | 65.6 |
| Avg Volume (50D)Average daily shares traded | 461K | 552K | 0 | 559K |
Analyst Outlook
Evenly matched — CCRN and PINC each lead in 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: GRDN as "Buy", CCRN as "Hold", PINC as "Hold", OMCL as "Hold". Consensus price targets imply 32.0% upside for OMCL (target: $57) vs -18.9% for CCRN (target: $11). PINC is the only dividend payer here at 2.98% yield — a key consideration for income-focused portfolios.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold | Hold | Hold |
| Price TargetConsensus 12-month target | $38.00 | $10.61 | $28.25 | $57.20 |
| # AnalystsCovering analysts | 3 | 14 | 31 | 19 |
| Dividend YieldAnnual dividend ÷ price | — | — | +3.0% | — |
| Dividend StreakConsecutive years of raises | 0 | 1 | 1 | — |
| Dividend / ShareAnnual DPS | — | — | $0.84 | — |
| Buyback YieldShare repurchases ÷ mkt cap | +1.3% | +1.6% | +17.1% | +3.9% |
GRDN leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). CCRN leads in 1 (Valuation Metrics). 2 tied.
GRDN vs CCRN vs PINC vs OMCL: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is GRDN or CCRN or PINC or OMCL a better buy right now?
For growth investors, Guardian Pharmacy Services, Inc.
(GRDN) is the stronger pick with 17. 9% revenue growth year-over-year, versus -21. 6% for Cross Country Healthcare, Inc. (CCRN). Guardian Pharmacy Services, Inc. (GRDN) offers the better valuation at 46. 5x trailing P/E (29. 6x forward), making it the more compelling value choice. Analysts rate Guardian Pharmacy Services, Inc. (GRDN) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — GRDN or CCRN or PINC or OMCL?
On trailing P/E, Guardian Pharmacy Services, Inc.
(GRDN) is the cheapest at 46. 5x versus Omnicell, Inc. at 978. 1x. On forward P/E, Premier, Inc. is actually cheaper at 20. 8x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — GRDN or CCRN or PINC or OMCL?
Over the past 5 years, Guardian Pharmacy Services, Inc.
(GRDN) delivered a total return of +126. 8%, compared to -69. 4% for Omnicell, Inc. (OMCL). Over 10 years, the gap is even starker: GRDN returned +126. 7% versus CCRN's -10. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — GRDN or CCRN or PINC or OMCL?
By beta (market sensitivity over 5 years), Premier, Inc.
(PINC) is the lower-risk stock at 0. 07β versus Omnicell, Inc. 's 1. 34β — meaning OMCL is approximately 1788% more volatile than PINC relative to the S&P 500. On balance sheet safety, Cross Country Healthcare, Inc. (CCRN) carries a lower debt/equity ratio of 1% versus 18% for Premier, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — GRDN or CCRN or PINC or OMCL?
By revenue growth (latest reported year), Guardian Pharmacy Services, Inc.
(GRDN) is pulling ahead at 17. 9% versus -21. 6% for Cross Country Healthcare, Inc. (CCRN). On earnings-per-share growth, the picture is similar: Guardian Pharmacy Services, Inc. grew EPS 144. 1% year-over-year, compared to -565. 9% for Cross Country Healthcare, Inc.. Over a 3-year CAGR, GRDN leads at 16. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — GRDN or CCRN or PINC or OMCL?
Guardian Pharmacy Services, Inc.
(GRDN) is the more profitable company, earning 3. 4% net margin versus -9. 0% for Cross Country Healthcare, Inc. — meaning it keeps 3. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GRDN leads at 6. 1% versus -0. 3% for CCRN. At the gross margin level — before operating expenses — PINC leads at 73. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is GRDN or CCRN or PINC or OMCL more undervalued right now?
On forward earnings alone, Premier, Inc.
(PINC) trades at 20. 8x forward P/E versus 133. 8x for Cross Country Healthcare, Inc. — 113. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for OMCL: 32. 0% to $57. 20.
08Which pays a better dividend — GRDN or CCRN or PINC or OMCL?
In this comparison, PINC (3.
0% yield) pays a dividend. GRDN, CCRN, OMCL do not pay a meaningful dividend and should not be held primarily for income.
09Is GRDN or CCRN or PINC or OMCL better for a retirement portfolio?
For long-horizon retirement investors, Premier, Inc.
(PINC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 07), 3. 0% yield). Both have compounded well over 10 years (PINC: -4. 6%, OMCL: +36. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between GRDN and CCRN and PINC and OMCL?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: GRDN is a small-cap high-growth stock; CCRN is a small-cap quality compounder stock; PINC is a small-cap quality compounder stock; OMCL is a small-cap quality compounder stock. PINC pays a dividend while GRDN, CCRN, OMCL do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.